Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $53.09 Consensus PT from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.0909.

A number of research firms have commented on JANX. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a report on Thursday, January 22nd. Piper Sandler cut their target price on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, January 16th. Clear Str downgraded Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Guggenheim lowered their price target on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, April 5th.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds have recently modified their holdings of the stock. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Janux Therapeutics in the fourth quarter worth about $34,000. Caitong International Asset Management Co. Ltd bought a new stake in Janux Therapeutics in the fourth quarter worth $51,000. Osaic Holdings Inc. raised its stake in Janux Therapeutics by 704.6% during the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after purchasing an additional 2,502 shares in the last quarter. Finally, Winthrop Capital Management LLC bought a new position in Janux Therapeutics during the third quarter valued at $106,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

JANX opened at $15.82 on Friday. The company has a 50 day simple moving average of $13.96 and a two-hundred day simple moving average of $18.33. The firm has a market cap of $962.33 million, a P/E ratio of -8.64 and a beta of 2.82. Janux Therapeutics has a 1-year low of $12.12 and a 1-year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. Equities analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.